• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Effect of tyrosine kinase inhibitor for immunological microenviroment of hepatocellular carcinoma

Research Project

Project/Area Number 18K07922
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53010:Gastroenterology-related
Research InstitutionKindai University

Principal Investigator

KUDO Masatoshi  近畿大学, 医学部, 教授 (10298953)

Co-Investigator(Kenkyū-buntansha) 西田 直生志  近畿大学, 医学部, 准教授 (60281755)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2019: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords肝細胞癌 / 微小免疫環境 / 免疫チェックポイント阻害剤 / チロシンキナーゼ阻害剤 / PI3K-Akt経路 / β-catenin経路 / b-カテニン経路 / 腫瘍免疫 / 遺伝子変異 / PI3K / βカテニン / 免疫チェックポイント / PD-L1 / 免疫微小環境 / 免疫
Outline of Final Research Achievements

To know how the effectively the response to immune checkpoint inhibitors (ICIs) can be enhanced, we explored the immunological and molecular characteristics of HCCs. Programmed cell death ligand 1 (PD-L1)-positive HCCs frequently showed inflamed phenotype; a subset of HCCs carried mutation in PI3K-Akt pathway. In HCCs with infiltration of TILs, CD8+ cells expressed multiple co-inhibitory receptors, suggesting T-cell exhaustion. On the other hands, PD-L1-negative HCCs showed activating mutations in β-catenin, such tumor exhibited non-inflamed phenotype. Through the analysis of the HCC patients treated with anti-PD-1 therapy, the combined of Wnt/β-catenin activation, PD-L1 expression, and degree of CD8+ TILs in HCC are revealed to be the predicting factor for the response to ICI. Tyrosine kinase inhibitor involving PI3K/Akt pathway, in combination with ICI, might effective in HCC with mutation in PI3K-Akt. Role of β-catenin inhibitor on immune cold HCC should also be explored.

Academic Significance and Societal Importance of the Research Achievements

PD-L1陽性肝癌は免疫細胞浸潤(TIL)が多く、しかしTILには複数の抑制型受容体が発現しており、PI3K-Akt変異例が比較的多い。従って、PI3K-Akt活性に介在するチロシンキナーゼ阻害剤が併用に有利である可能性がある。PD-L1陰性肝癌はTILに乏しく β-カテニン経路活性型変異を持つ。β-カテニン阻害剤の腫瘍免疫への影響を検討する余地がある。PD-L1発現肝癌は、CK-19やSALL4陽性例が多いが、従来治療に難治であり、ICIとPI3K-Ak阻害剤併用に期待が持たれる。TILに複数の抑制型受容体が発現していることより、2種の抑制型受容体に対する複合免疫療法にも期待される。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (45 results)

All 2021 2020 2019 2018

All Journal Article (24 results) (of which Int'l Joint Research: 8 results,  Peer Reviewed: 24 results,  Open Access: 15 results) Presentation (16 results) (of which Int'l Joint Research: 10 results,  Invited: 5 results) Book (5 results)

  • [Journal Article] Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.2021

    • Author(s)
      Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N.
    • Journal Title

      Cancers (Basel).

      Volume: 12 Issue: 10 Pages: 3048-3048

    • DOI

      10.3390/cancers12103048

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The Efficacy of Sonazoid-enhanced Ultrasonography in Decision-making for Liver Abscess Treatment2020

    • Author(s)
      Morita M, Ogawa C, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Seno H, Minami Y, Ueshima K, Sakurai T, Nishida N, Kudo M.
    • Journal Title

      Internal Medicine

      Volume: 59 Issue: 4 Pages: 471-477

    • DOI

      10.2169/internalmedicine.2510-18

    • NAID

      130007798491

    • ISSN
      0918-2918, 1349-7235
    • Year and Date
      2020-02-15
    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents2020

    • Author(s)
      Sakurai Toshiharu、Nishida Naoshi、Kudo Masatoshi
    • Journal Title

      Hepatobiliary Surgery and Nutrition

      Volume: 9 Issue: 6 Pages: 777-779

    • DOI

      10.21037/hbsn.2020.03.04

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma.2020

    • Author(s)
      Naoshi Nishida
    • Journal Title

      Hepatobiliary surgery and nutrition

      Volume: 9 Issue: 5 Pages: 640-643

    • DOI

      10.21037/hbsn.2019.10.18

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-12020

    • Author(s)
      Nishida Naoshi、Sakai Kazuko、Morita Masahiro、Aoki Tomoko、Takita Masahiro、Hagiwara Satoru、Komeda Yoriaki、Takenaka Mamoru、Minami Yasunori、Ida Hiroshi、Ueshima Kazuomi、Nishio Kazuto、Kudo Masatoshi
    • Journal Title

      Liver Cancer

      Volume: 9 Issue: 4 Pages: 426-439

    • DOI

      10.1159/000506352

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma.2020

    • Author(s)
      Naoshi Nishida, Masatoshi Kudo
    • Journal Title

      Cancers

      Volume: 12 Issue: 5 Pages: 1274-1274

    • DOI

      10.3390/cancers12051274

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability.2020

    • Author(s)
      Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.
    • Journal Title

      Hepatol Res.

      Volume: 50 Issue: 1 Pages: 67-74

    • DOI

      10.1111/hepr.13407

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.2019

    • Author(s)
      Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N.
    • Journal Title

      Cancers (Basel)

      Volume: 11 Issue: 8 Pages: 1084-1084

    • DOI

      10.3390/cancers11081084

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.2019

    • Author(s)
      Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M.
    • Journal Title

      Cancers (Basel)

      Volume: 11 Issue: 7 Pages: 952-952

    • DOI

      10.3390/cancers11070952

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.2019

    • Author(s)
      Minami Y, Nishida N, Kudo M
    • Journal Title

      Eur Radiol.

      Volume: 29 Issue: 9 Pages: 5045-5051

    • DOI

      10.1007/s00330-019-06189-6

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology.2019

    • Author(s)
      Nishida N, Yamakawa M, Shiina T, Kudo M.
    • Journal Title

      Hepatol Int.

      Volume: 印刷中 Issue: 4 Pages: 416-421

    • DOI

      10.1007/s12072-019-09937-4

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis.2019

    • Author(s)
      Kono M, Sakurai T, Okamoto K, Masaki S, Nagai T, Komeda Y, Kamata K, Minaga K, Yamao K, Takenaka M, Watanabe T, Nishida N, Kudo M.
    • Journal Title

      Intern Med.

      Volume: 58 Pages: 1263-1266

    • NAID

      130007641397

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Liver damage related to immune checkpoint inhibitors.2019

    • Author(s)
      Nishida N, Kudo M
    • Journal Title

      Hepatol Int

      Volume: 印刷中 Issue: 3 Pages: 248-252

    • DOI

      10.1007/s12072-018-9921-7

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.2019

    • Author(s)
      Kudo M
    • Journal Title

      Liver Cancer

      Volume: 8 Issue: 1 Pages: 1-11

    • DOI

      10.1159/000496277

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.2019

    • Author(s)
      Kudo M
    • Journal Title

      World J Gastroenterol

      Volume: 25 Issue: 7 Pages: 789-807

    • DOI

      10.3748/wjg.v25.i7.789

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.2019

    • Author(s)
      Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, Meier G, Pan J, Ishii M, Ikeda S
    • Journal Title

      J Gastroenterol

      Volume: 印刷中 Issue: 6 Pages: 558-570

    • DOI

      10.1007/s00535-019-01554-0

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.2019

    • Author(s)
      Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators
    • Journal Title

      Lancet Oncol.

      Volume: 20 Issue: 2 Pages: 282-296

    • DOI

      10.1016/s1470-2045(18)30937-9

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency2018

    • Author(s)
      Yokomichi Naosuke、Nishida Naoshi、Umeda Yuzo、Taniguchi Fumitaka、Yasui Kazuya、Toshima Toshiaki、Mori Yoshiko、Nyuya Akihiro、Tanaka Takehiro、Yamada Takeshi、Yagi Takahito、Fujiwara Toshiyoshi、Yamaguchi Yoshiyuki、Goel Ajay、Kudo Masatoshi、Nagasaka Takeshi
    • Journal Title

      Liver Cancer

      Volume: none Issue: 4 Pages: 1-16

    • DOI

      10.1159/000490806

    • Related Report
      2019 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.2018

    • Author(s)
      Kudo M
    • Journal Title

      Cancers (Basel)

      Volume: 30 Issue: 11 Pages: 412-412

    • DOI

      10.3390/cancers10110412

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.2018

    • Author(s)
      Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, Kudo M, Kumada T, Roayaie S, Johnson PJ.
    • Journal Title

      J Hepatol.

      Volume: 69 Issue: 6 Pages: 1284-1293

    • DOI

      10.1016/j.jhep.2018.08.027

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study2018

    • Author(s)
      Kudo M, Kang YK, Park JW, Qin S, Inaba Y, Assenat E, Umeyama Y, Lechuga MJ, Valota O, Fujii Y, Martini JF, Williams JA, Obi S.
    • Journal Title

      Liver Cancer.

      Volume: 7 Issue: 2 Pages: 148

    • DOI

      10.1159/000484620

    • URL

      https://pure.teikyo.jp/en/publications/39ecc66b-0e8a-41be-a79c-9015243c66d8

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.2018

    • Author(s)
      Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators.
    • Journal Title

      Lancet Oncol. 2018 Jul;19(7):940-952

      Volume: 19 Issue: 7 Pages: 940-952

    • DOI

      10.1016/s1470-2045(18)30351-6

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial2018

    • Author(s)
      Kudo M、Ueshima K、Yokosuka O、Ogasawara S、Obi S、Izumi N、Aikata H、Nagano H、Hatano E、Sasaki Y、Hino K、Kumada T、Yamamoto K、Imai Y、Iwadou S、Ogawa C、Okusaka T、Kanai F、Akazawa K、Yoshimura K、Johnson P、Arai Y
    • Journal Title

      The Lancet Gastroenterology & Hepatology

      Volume: 3 Issue: 6 Pages: 424-432

    • DOI

      10.1016/s2468-1253(18)30078-5

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.2018

    • Author(s)
      Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL.
    • Journal Title

      Lancet. 2018 Mar 24;391(10126):1163-1173

      Volume: 24 Issue: 10126 Pages: 1163-1173

    • DOI

      10.1016/s0140-6736(18)30207-1

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Presentation] 肝細胞癌の遺伝子異常による分類と微小免疫環境2020

    • Author(s)
      西田直生志, 工藤正俊
    • Organizer
      第56回日本肝癌研究会 WS03. 肝細胞癌の亜分類
    • Related Report
      2020 Annual Research Report
  • [Presentation] 進行肝癌に対する免疫チェックポイント阻害剤後レンバチニブ療法の画像評価2020

    • Author(s)
      青木智子, 依田広, 盛田真弘, 南知宏, 田北雅弘, 萩原智, 南康範, 上嶋一臣, 西田直生志, 工藤正俊
    • Organizer
      日本超音波医学会第93回学術集会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 免疫チェックポイント阻害剤登場後のレンバチニブの位置づけ2020

    • Author(s)
      青木智子, 上嶋一巨, 盛田真弘, 田北雅弘, 萩原智, 南康範, 依田広, 西田直生志, 鶴崎正勝, 工藤正俊
    • Organizer
      第22回日本肝がん分子標的療法研究会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 肝細胞癌における腫瘍免疫環境と癌関連分子の遺伝子変異2020

    • Author(s)
      西田直生志, 盛田真弘, 工藤正俊
    • Organizer
      第28回 日本消化器関連学会週間, シンポジウム3 肝癌診療の現状と未来
    • Related Report
      2020 Annual Research Report
  • [Presentation] HCC Immunotherapy and Immuno-Phenotype2019

    • Author(s)
      Naoshi Nishida
    • Organizer
      CHA International Gastrointestinal Disease Forum
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research / Invited
  • [Presentation] OBJECTIVE RESPONSE BY MRECIST IS A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL IN UNRESECTABLE HEPATOCELLULAR CARCINOMA TREATED WITH SYSTEMIC THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS2019

    • Author(s)
      Masatoshi Kudo, Kazuomi Ueshima, Naoshi Nishida
    • Organizer
      American Society for the Study of Liver Disease (AASLD)
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research
  • [Presentation] IMPACT OF BASELINE ALBI GRADE ON THE OUTCOMES OF HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIB: A MULTICENTER STUDY2019

    • Author(s)
      Masatoshi Kudo, Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara, Tomoko Aoki, Tomohiro Minami, Hirokazu Chishina, Masahiro Takita, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Masahiro Morita, Chikara Ogawa, Atsushi Hiraoka
    • Organizer
      American Society for the Study of Liver Disease (AASLD)
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research
  • [Presentation] LENVATINIB AS AN INITIAL TREATMENT IN PATIENTS WITH INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA BEYOND UP-TO-SEVEN CRITERIA AND CHILD-PUGH A LIVER FUNCTION: A MULTICENTER PROPENSITY-SCORE MATCHED STUDY2019

    • Author(s)
      Kazuomi Ueshima, Stephen L. Chan, Tomohiro Minami, Hirokazu Chishina, Tomoko Aoki, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Masahiro Morita, Chikara Ogawa, Yoshiyuki Wada, Masafumi Ikeda, Hiroshi Ishii, Namiki Izumi, Naoshi Nishida
    • Organizer
      American Society for the Study of Liver Disease (AASLD)
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research
  • [Presentation] 肝細胞癌における薬物療法の展開2019

    • Author(s)
      西田 直生志
    • Organizer
      Kansai Liver Forum
    • Related Report
      2019 Research-status Report
    • Invited
  • [Presentation] 肝細胞癌の薬物治療2019

    • Author(s)
      西田 直生志
    • Organizer
      日本肝臓学会教育講演会
    • Related Report
      2019 Research-status Report
    • Invited
  • [Presentation] Recent advancement of molecular targeted therapy in hepatocellular carcinoma2019

    • Author(s)
      Naoshi Nishida
    • Organizer
      The Asian Pacific Association for the Study of the Liver APASL Single Topic Conference “Liver Immunology and Genetics”
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research / Invited
  • [Presentation] Evolving roles of targeted therapy in HCC2019

    • Author(s)
      工藤正俊
    • Organizer
      the 3rd Symposium of the Singapore Liver Cancer Consortium (SLCC)
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research / Invited
  • [Presentation] Lenvatinib (lenva) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study2019

    • Author(s)
      Kudo Masatoshi
    • Organizer
      American Society of Clinical Oncology Annual Meeting
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] A phase 1b trial of Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results.2019

    • Author(s)
      Kudo Masatoshi
    • Organizer
      American Association for Cancer Research Annual Meeting (AACR 2019)
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis2019

    • Author(s)
      Kudo Masatoshi
    • Organizer
      The International Iiver Congress (EASL 2019)
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): an analysis of AFP kinetics in the phase 3 REACH-2 study.2019

    • Author(s)
      Kudo Masatoshi
    • Organizer
      American Society of Clinical Oncology, Gastrointestinal Cancers Symposium (ASCO-GI 2019)
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Book] 肝・胆・膵-肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part I-(免疫療法)】2020

    • Author(s)
      西田 直生志, 工藤 正俊
    • Total Pages
      8
    • Publisher
      (株)アークメディア
    • Related Report
      2020 Annual Research Report
  • [Book] 肝・胆・膵【肝細胞性腫瘍の分類・亜分類の最前線】肝細胞癌 肝癌の治療からみた亜型分類2020

    • Author(s)
      盛田 真弘, 西田 直生志
    • Total Pages
      11
    • Publisher
      (株)アークメディア
    • Related Report
      2020 Annual Research Report
  • [Book] 腫瘍内科【肝・胆・膵がんの薬物療法】肝細胞がん 肝細胞がんの全身薬物療法開発の動向2020

    • Author(s)
      西田 直生志
    • Total Pages
      8
    • Publisher
      有)科学評論社
    • Related Report
      2020 Annual Research Report
  • [Book] Diagnosis of Liver Disease, Liver Tumors II: Malignant Tumors of the Liver2019

    • Author(s)
      Naoshi Nishida, Ryuichi Kita, Kenichi Miyoshi, Masahiko Koda, Masaki Iwai, Arief. A. Suriawinata
    • Total Pages
      34
    • Publisher
      Springer Nature
    • ISBN
      9811368058
    • Related Report
      2019 Research-status Report
  • [Book] ESMO Handobook of IMMUNO-ONCOLOGY2018

    • Author(s)
      Kudo Masatoshi
    • Total Pages
      3
    • Publisher
      ESMO Press
    • ISBN
      9788894179576
    • Related Report
      2018 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi